Back to top
more

Better trading starts here.

Brokerage Reports

Research for IPHA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

2 items in cart

View Cart/Checkout

Innate Pharma S.A. Sponsored ADR [IPHA]

Reports for Purchase

Showing records 21 - 30 ( 30 total )

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 21

03/19/2021

Company Report

Pages: 7

Executing Pipeline Advancement Strategy; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 22

12/14/2020

Company Report

Pages: 6

Re-Prioritize R&D Over Commercialization; Adjust PT to $11.50; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 23

11/18/2020

Company Report

Pages: 7

Monalizumab Advanced Into Pivotal; COVID-19 Study Expanded; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 24

09/09/2020

Company Report

Pages: 7

Collaboration Amendment Is Not as Bad as it Looks; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 25

06/02/2020

Daily Note

Pages: 4

Positive Monalizumab Update at ASCO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 26

05/14/2020

Company Report

Pages: 7

Monalizumab Phase 2 Update at ASCO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 27

03/11/2020

Company Report

Pages: 7

Lumoxiti Transition on Target; Catalyst Rich 2020; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 28

01/03/2020

Daily Note

Pages: 3

Lumoxiti MAA Accepted and on Track for 4Q20 Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 29

12/10/2019

Daily Note

Pages: 4

Favorable Long-Term Data: A Positive for Lumoxiti Adoption; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 30

11/26/2019

Company Report

Pages: 6

Strong Commercial and Clinical Progress; Reiterate Buy; Adjusting to $13.00 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party